Plasma metabolomic profiles in breast cancer patients and healthy controls: By race and tumor receptor subtypes

Translational Oncology

Volumn 6, Issue 6, 2013, Pages 757-765

  Shen, Jie ^a   Yan, Li ^b   Liu, Song ^b   Ambrosone, Christine B ^b   Zhao, Hua ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84891677915     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.13619     Document Type: Article

References (41)

1. Claudino WM, Goncalves PH, di Leo A, and Philip PA (2012). Metabolomics in cancer: a bench-to-bedside intersection. Crit Rev Oncol Hematol 84, 1-7.
2. Patti GJ, Yanes O, and Siuzdak G (2012). Innovation: metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol 13, 263-269.
3. Go VL, Nguyen CT, Harris DM, and Lee WN (2005). Nutrient-gene interaction: metabolic genotype-phenotype relationship. J Nutr 135, 3016S-3020S.
4. Bictash M, Ebbels TM, Chan Q, Loo RL, Yap IK, Brown IJ, de Iorio M, Daviglus ML, Holmes E, Stamler J, et al. (2010). Opening up the "Black Box": metabolic phenotyping and metabolome-wide association studies in epidemiology. J Clin Epidemiol 63, 970-979.
5. Yamaguchi M (2013). Suppressive role of regucalcin in liver cell proliferation: involvement in carcinogenesis. Cell Prolif 46, 243-253.
6. Holland JD, Klaus A, Garratt AN, and Birchmeier W (2013). Wnt signaling in stem and cancer stem cells. Curr Opin Cell Biol 25, 254-264.
7. Yue W, Yager JD, Wang JP, Jupe ER, and Santen RJ (2013). Estrogen receptordependent and independent mechanisms of breast cancer carcinogenesis. Steroids 78, 161-170.
8. Giskeødegård GF, Grinde MT, Sitter B, Axelson DE, Lundgren S, Fjøsne HE, Dahl S, Gribbestad IS, and Bathen TF (2010). Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics. J Proteome Res 9, 972-979.
9. Sitter B, Bathen TF, Singstad TE, Fjøsne HE, Lundgren S, Halgunset J, and Gribbestad IS (2010). Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy. NMR Biomed 23, 424-431.
10. Asiago VM, Alvarado LZ, Shanaiah N, Gowda GA, Owusu-Sarfo K, Ballas RA, and Raftery D (2010). Early detection of recurrent breast cancer using metabolite profiling. Cancer Res 70, 8309-8318.
11. Borgan E, Sitter B, Lingjærde OC, Johnsen H, Lundgren S, Bathen TF, Sørlie T, Børresen-Dale AL, and Gribbestad IS (2010). Merging transcriptomics and metabolomics-advances in breast cancer profiling. BMC Cancer 10, 628.
12. Slupsky CM, Steed H, Wells TH, Dabbs K, Schepansky A, Capstick V, Faught W, and Sawyer MB (2010). Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin Cancer Res 16, 5835-5841.
13. Nam H, Chung BC, Kim Y, Lee K, and Lee D (2009). Combining tissue transcriptomics and urine metabolomics for breast cancer biomarker identification. Bioinformatics 25, 3151-3157.
14. Sugimoto M, Wong DT, Hirayama A, Soga T, and Tomita M (2010). Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics 6, 78-95.
15. Ambrosone CB, Nesline MK, and Davis W (2006). Establishing a cancer center data bank and biorepository for multidisciplinary research. Cancer Epidemiol Biomarkers Prev 15, 1575-1577.
16. Kuhajda FP (2006). Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 66, 5977-5980.
17. Chlebowski RT, Chen Z, Anderson GL, Rohan T, Aragaki A, Lane D, Dolan NC, Paskett ED, McTiernan A, Hubbell FA, et al. (2005). Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 97, 439-448.
18. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, et al. (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295, 2492-2502.
19. Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, Lee MM, Ambrosone CB, and Caan BJ (2009). Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 11, R31.
20. Mavaddat N, Antoniou AC, Easton DF, and Garcia-Closas M (2010). Genetic susceptibility to breast cancer. Mol Oncol 4, 174-191.
21. Amirikia KC, Mills P, Bush J, and Newman LA (2011). Higher populationbased incidence rates of triple-negative breast cancer among young African-American women. Cancer 117, 2747-2753.
22. Collaborative Group on Hormonal Factors in Breast Cancer (2001). Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58, 209 women with breast cancer and 101, 986 women without the disease. Lancet 358, 1389-1399.
23. Pharoah PDP, Antoniou AC, Easton DF, and Ponder BAJ (2008). Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 358, 2796-2803.
24. Gieger C, Geistlinger L, Altmaier E, Hrabé de Angelis M, Kronenberg F, Meitinger T, Mewes HW, Wichmann HE, Weinberger KM, Adamski J, et al. (2008). Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. PLoS Genet 4, e1000282.
25. Chin KY, Mo H, and Ima-Nirwana S (2013). A review of the possible mechanisms of action of tocotrienol-a potential antiosteoporotic agent. Curr Drug Targets 14, 1533-1541.
26. Miyagi Y, Higashiyama M, Gochi A, and Akaike M (2011). Plasma free amino acid profiling of five types of cancer patients and its application for early detection. PLoS One 6, e24143.
27. 1H NMR-based metabolomics. Neoplasia 11, 269-276.
28. Heber D, Byerly LO, and Chlebowski RT (1985). Metabolic abnormalities in the cancer patient. Cancer 55, 225-229.
29. Bennegård K, Lindmark L, Edén E, Svaninger G, and Lundholm K (1984). Flux of amino acids across the leg in weight-losing cancer patients. Cancer Res 44, 386-393.
30. Proenza AM, Oliver J, Palou A, and Roca P (2003). Breast and lung cancer are associated with a decrease in blood cell amino acid content. J Nutr Biochem 14, 133-138.
31. Cascino A, Muscaritoli M, Cangiano C, Conversano L, Laviano A, Ariemma S, Meguid MM, and Rossi Fanelli F (1995). Plasma amino acid imbalance in patients with lung and breast cancer. Anticancer Res 15, 507-510.
32. Lai HS, Lee JC, Lee PH, Wang ST, and Chen WJ (2005). Plasma free amino acid profile in cancer patients. Semin Cancer Biol 15, 267-276.
33. Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW, and Cravatt BF (2010). Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 140, 49-61.
34. Nieman KM, Romero IL, Van Houten B, and Lengyel E (2013). Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta 1831, 1533-1541.
35. Soto-Guzman A, Navarro-Tito N, Castro-Sanchez L, Martinez-Orozco R, and Salazar EP (2010). Oleic acid promotes MMP-9 secretion and invasion in breast cancer cells. Clin Exp Metastasis 27, 505-515.
36. Serra D, Mera P, Malandrino MI, Mir JF, and Herrero L (2013). Mitochondrial fatty acid oxidation in obesity. Antioxid Redox Signal 19, 269-284.
37. Navarro-Tito N, Soto-Guzman A, Castro-Sanchez L, Martinez-Orozco R, and Salazar EP (2010). Oleic acid promotes migration on MDA-MB-231 breast cancer cells through an arachidonic acid-dependent pathway. Int J Biochem Cell Biol 42, 306-317.
38. Wall R, Ross RP, Fitzgerald GF, and Stanton C (2010). Fatty acids fromfish: the antiinflammatory potential of long-chain omega-3 fatty acids. Nutr Rev 68, 280-289.
39. Zhang H, Zhou L, Shi W, Song N, Tu K, and Gu Y (2012). A mechanism underlying the effects of polyunsaturated fatty acids on breast cancer. Int J Mol Med 30, 487-494.
40. Li J, Humphreys K, Heikkinen T, Aittomäki K, Blomqvist C, Pharoah PD, Dunning AM, Ahmed S, Hooning MJ, Martens JW, et al. (2011). A combined analysis of genome-wide association studies in breast cancer. Breast Cancer Res Treat 126, 717-727.
41. Lewis GD, Farrell L, Wood MJ, Martinovic M, Arany Z, Rowe GC, Souza A, Cheng S, McCabe EL, Yang E, et al. (2010). Metabolic signatures of exercise in human plasma. Sci Transl Med 2, 33ra7.